There are many other patents related to ARL4C (Table 3), such as short (or small) activating RNA (saRNA, patent number: JP2021035360A and JP2018512876A6), RNA encoding a therapeutic protein (patent number: US20190241633A1), immunotherapy (patent number: US20200157633A1, US20200016202A1, WO2017069958A2, and US20140073526A1), sudden cardiac event (patent number: AU2011227108A1), cardiac developmental (patent number: WO2018007525A2), dysregulated lipid metabolism (patent number: US20230132366A9 and US20200360375A1), pulmonary arterial hypertension (PAH, patent number: WO2017089593A1). This evidence concerns the gene ARL4C and pulmonary arterial hypertension.